The side effect of Ozempika, which leads to blindness, has been identified in the EU

The European Medical Agency (EMA) has discovered a very rare side effect of the well-known diabetes drug Ozempik, which can lead to vision loss. This was reported on June 6 by Bloomberg with reference to the EMA statement.

"An eye disease called NAION (non-arterial anterior ischemic optic neuropathy. — Ed.), is a "very rare" side effect of semaglutide, a key ingredient in diabetes and obesity medications. This may affect up to one in 10,000 people taking medications," the agency said in a statement.

It is specified that this disease occurs after a violation of blood flow damages the optic nerve. It is irreversible, untreatable, and can lead to complete blindness.

According to the agency, as a result of two studies conducted by the EMA, it was found that people with type 2 diabetes who took Ozempik had twice the risk of developing eye diseases. The EMA recommends that manufacturers of semaglutide drugs update their instructions and include data on NAION.

"If patients experience sudden vision loss or rapid deterioration during semaglutide treatment, they should contact their doctor immediately," the EMA concluded.

Rebel belly: what is the threat of using drugs for weight loss

The girl was hospitalized after taking pills from the Internet

Back on February 10, the Daily Mail reported that in the United States, more and more residents who use Ozempik, a drug for diabetes and weight loss, are experiencing vision loss. The publication told about a woman who had an injection for diabetes and woke up the next morning blind in her left eye.